Formulation Development
Melt Pharmaceuticals Completes Phase 1 Study for Sublingual, Non-Opioid Pain & Sedation Drug Candidate
Melt Pharmaceuticals, Inc. recently announced results from its MELT Phase 1 study, a comparative bioavailability study with the objective of characterizing the pharmacokinetic parameters of…
uniQure Announces Positive Recommendation From Data Safety Monitoring Board of Phase 1/2 Clinical Trial
uniQure N.V. recently announced that the independent Data Safety Monitoring Board (DSMB) overseeing the Phase 1/2 clinical trial of AMT-130 for the treatment of Huntington’s…
Hyloris & Purna Female Healthcare Announce Development Partnership
Hyloris Pharmaceuticals SA and Purna Female Healthcare recently announced they have entered into a partnership to develop and commercialize an innovative combination therapy for the…
Emerald Health Pharmaceuticals Demonstrates Potential Disease-Modifying Activity of Novel Product Candidate With Multi-Modal Mechanism of Action in Parkinson’s Disease
Emerald Health Pharmaceuticals Inc. recently published a scientific article in the peer-reviewed journal, Molecular and Cellular Neuroscience, highlighting data supporting the potential of EHP’s drug…
Trizell Signs Development & Manufacturing Agreement With Catalent for Macrophage-Based Advanced Cell Therapy
Catalent recently announced it has signed an agreement with Trizell GmbH, to support the manufacturing of Trizell’s Phase 1 cell therapy for the treatment of…
ProPerma™ Oral Formulation Technology
ProPerma™ uniquely improves both permeability and bioavailability of BCS III and BCS IV compounds by deploying an innovative and bespoke combination of GRAS and novel enhancing excipients…
Ensure Drug Development Success: Recipharm's Expertise at Your Disposal
Developing a new pharmaceutical product is one of the most interesting and rewarding activities to partake in, it is also extremely challenging. It is a given that drug development projects will not….
Theratechnologies’ Lead Peptide Drug Conjugate TH1902 Receives FDA Fast-Track Designation
Theratechnologies Inc. recently announced the US FDA has granted fast-track designation to TH1902 as a single agent for the treatment of patients with sortilin positive…
Decibel & Catalent Sign Development & Manufacturing Agreement for Dual-Vector Gene Therapy for the Treatment of Congenital Hearing
Catalent and Decibel Therapeutics recently announced they have signed an agreement for Catalent to provide Decibel with process and analytical development, and CGMP clinical manufacturing…
Biogen Announces FDA Approval of PLEGRIDY (Peginterferon Beta-1a) Intramuscular Administration for Multiple Sclerosis
Biogen Inc. recently announced the US FDA has approved a new intramuscular (IM) injection route of administration for PLEGRIDY (peginterferon beta-1a) for the treatment of….
Beroni Acquires Majority Interest in Anti-Cancer Drug Development Company
Beroni Group recently announced it has completed its majority acquisition of the Sydney-based anti-cancer drug development company, PENAO Pty Ltd. As a result of this acquisition….
Albumedix Collaborates With CGT Catapult to Advance Cell & Gene Therapies
Albumedix Ltd. recently announced it has entered into a collaboration agreement with the Cell and Gene Therapy Catapult (CGT Catapult) to investigate the use of Albumedix´ proprietary albumin-based solutions for….
X-Chem Enters Multitarget Oncology Discovery Research Collaboration & License Agreement With Genentech
X-Chem, Inc. recently announced it has entered into a research collaboration and license agreement with Genentech, a member of the Roche Group. The goal of…
Gerresheimer Has Optimized the Test Cartridge & Reagent Block for Ergonomic Handling & Plastic-Suitable Production
Medical technology specialist Gerresheimer has developed the test cartridge and reagent block for a fully automatic blood analyzer that can be used to identify a…
GSK & CureVac to Develop Next-Generation mRNA COVID-19 Vaccines
GlaxoSmithKline plc and CureVac N.V. recently announced a new €150-million collaboration, building on their existing relationship, to jointly develop next-generation mRNA vaccines for COVID-19 with…
Crinetics Pharmaceuticals Lead ACTH Antagonist for Congenital Adrenal Hyperplasia & Cushing’s Disease Advances Into Phase 1 Study
Crinetics Pharmaceuticals, Inc. recently announced that CRN04894, the company’s lead adrenocorticotropic hormone (ACTH) antagonist for the treatment of diseases associated with excess ACTH such as Cushing’s…
Venthera Doses First Patient With Topical Therapy Targeting Genetic Drivers of Rare Vascular Anomalies
BridgeBio Pharma, Inc. and affiliate Venthera recently announced the first subject has been dosed in its Phase 1/2 clinical trial of BBP-681 (also known as…
Cerba Research Announces Time-Saving COVID-19 Exploratory Tools & NGS Advancements
Cerba Research recently announced it has developed two new COVID-19 exploratory tools to enhance clinical research for the development of vaccines and treatments for COVID-19 and other infectious diseases…..
Pacira BioSciences Announces Equity Investment in GeneQuine Biotherapeutics
Pacira BioSciences, Inc. recently announced that the company will lead an equity investment in GeneQuine Biotherapeutics GmbH…..
Relief Therapeutics & Acer Therapeutics Sign Option Agreement for Exclusivity to Negotiate a Collaboration & License Agreement
Relief Therapeutics Holding AG and Acer Therapeutics Inc. recently announced the companies have signed an Option Agreement providing exclusivity for the right to negotiate a potential collaboration and license….
